Articles dans des revues avec comité de lecture (167)
  1. 8. Najem, A., Wouters, J., Krayem, M., Rambow, F., Sabbah, M., Sales, F., Awada, A., Aerts, S., Journé, F., Marine, J.-C., & Ghanem, G. E. (2021). Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value. Frontiers in oncology, 11, 780654. doi:10.3389/fonc.2021.780654
  2. 9. Berehab, M., Rouas, R., Akl, H., Duvillier, H., Journé, F., Fayyad Kazan, H., Ghanem, G. E., Bron, D., Lewalle, P., & Merimi, M. (2021). Apoptotic and non-apoptotic modalities of thymoquinone-induced lymphoma cell death: Highlight of the role of cytosolic calcium and necroptosis. Cancers (Basel), 13(14), 3579. doi:10.3390/cancers13143579
  3. 10. Sabbah, M., Krayem, M., Najem, A., Sales, F., Miller, W. W., Del Rincón, S. S., Awada, A., Ghanem, G. E., & Journé, F. (2021). Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-kit. Molecular cancer research, 19(7), 1221-1233. doi:10.1158/1541-7786.MCR-20-1040
  4. 11. Atak, Z. K., Taskiran, I. I., Demeulemeester, J., Flerin, C., Mauduit, D., Minnoye, L., Hulselmans, G., Christiaens, V., Ghanem, G. E., Wouters, J., & Aerts, S. (2021). Interpretation of allele-specific chromatin accessibility using cell state–aware deep learning. Genome research, 31(6), 1082-1096. doi:10.1101/gr.260851.120
  5. 12. Delbart, W., Ghanem, G. E., Karfis, I., Flamen, P., & Wimana, Z. (2021). Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines. Nuclear medicine and biology, 96-97, 68-79. doi:10.1016/j.nucmedbio.2021.03.006
  6. 13. Sabbah, M., Najem, A., Krayem, M., Awada, A., Journé, F., & Ghanem, G. E. (2021). Rtk inhibitors in melanoma: From bench to bedside. Cancers (Basel), 13(7), 1685. doi:10.3390/cancers13071685
  7. 14. Cogels, M., Rouas, R., Ghanem, G. E., Martinive, P., Awada, A., Van Gestel, D., & Krayem, M. (2021). Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research. Frontiers in oncology, 11, 784947. doi:10.3389/fonc.2021.784947
  8. 15. Krayem, M., Aftimos, P., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2020). Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title. Cancers (Basel), 12(10), 2981, 1-2. doi:10.3390/cancers12102981
  9. 16. Soumoy, L., Wells, M., Najem, A., Krayem, M., Ghanem, G. E., Hambÿe, S., Saussez, S., Blankert, B., & Journé, F. (2020). Toad venom antiproliferative activities on metastatic melanoma: Bio-guided fractionation and screening of the compounds of two different venoms. Biology, 9(8), 218, 1-16. doi:10.3390/biology9080218
  10. 17. Soumoy, L., Schepkens, C., Krayem, M., Najem, A., Tagliatti, V., Ghanem, G. E., Saussez, S., Colet, J.-M., & Journé, F. (2020). Metabolic reprogramming in metastatic melanoma with acquired resistance to targeted therapies: Integrative metabolomic and proteomic analysis. Cancers (Basel), 12(5), 1323. doi:10.3390/cancers12051323
  11. 18. Tétu, P., Delyon, J., André, J., De Moura, C. R., Sabbah, M., Ghanem, G. E., Batistella, M., Mourah, S., Lebbe, C., & Dumaz, N. (2020). Fgf2 induces resistance to nilotinib through mapk pathway activation in kit mutated melanoma. Cancers (Basel), 12(5), 1062. doi:10.3390/cancers12051062
  12. 19. Krayem, M., Aftimos, P., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2020). Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers (Basel), 12(2). doi:10.3390/cancers12020512
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Suivant >>